Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06524882 · ClinicalTrials.gov registry record · Phase 3
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
A Phase 3 study of Amblyopia, sponsored by Jaeb Center for Health Research.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 252
- Enrollment target
- 20
- Study locations
NCT06524882: Recruiting Phase 3 study of Amblyopia, sponsored by Jaeb Center for Health Research.
NCT06524882 is a Phase 3 study of Amblyopia that is actively recruiting participants, run by Jaeb Center for Health Research. The registered enrollment target is 252 participants, above the 155-participant average among 24 other Amblyopia trials with a reported enrollment target (63% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06524882, a Phase 3 study of Amblyopia, is actively recruiting participants, sponsored by Jaeb Center for Health Research.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 252 participants
- Enrollment target
- 20
- Study locations
Study Summary
Participants eligible for the study will be randomly allocated (1:1:1) to receive either Luminopia dichoptic treatment while wearing optical correction if needed, Vivid Vision dichoptic treatment while wearing optical correction if needed, or continued optical correction alone if needed, with clinical assessments at 9- and 18-weeks post-randomization. At the 18-week primary outcome visit, participants who were randomly assigned to receive optical correction alone if needed with an IOD of 1 logMAR line (5 letters) or more, will be offered randomization to Luminopia or Vivid Vision dichoptic therapy and if they accept, followed forward with visits at 27- and 36-weeks post-randomization. The study will end for all other participants at 18 weeks.
Primary Outcome
between randomization and 18 weeks
Conditions Studied
Interventions
- DEVICE Luminopia
- DEVICE Vivid Vision
- DEVICE Optical Correction
Study Locations (20)
California
- University Eye Center at Ketchum Health - Anaheim
- Univ. of California- Berkeley - Berkeley
- Univ of California, Irvine- Gavin Herbert Eye Institute - Irvine
- Stanford University - Palo Alto
- Western University College of Optometry - Pomona
- University of California, Davis - Sacramento
- University of California San Francisco Department of Ophthalmology - San Francisco
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
- Illinois College of Optometry - Chicago
- Midwestern University Eye Institute - Downers Grove
- Progressive Eye Care - Lisle
Arizona
- Midwestern University Eye Institute - Glendale
- Phoenix Children's Medical Group - Ophthalmology - Scottsdale
- University of Arizona - Tucson
Arkansas
- Arkansas Childrens - Little Rock
- McFarland Eye Care Center - Little Rock
Florida
- Nova Southeastern University College of Optometry, The Eye Institute - Fort Lauderdale
- University of South Florida (USF) Eye - Tampa
Alabama
- UAB Pediatric Eye Care; Birmingham Health Care - Birmingham
Indiana
- Indiana School of Optometry - Bloomington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 3 |
What NCT06524882 shows while recruiting
NCT06524882 is an interventional study that assigns participants to a tested intervention. The registered 252 participants enrollment target is mid-sized for trials with a published cap, above the 155-participant average among 24 other Amblyopia trials with a reported enrollment target (63% higher).
The record links to 1 condition, with Amblyopia appearing as the primary indexed condition, and to 3 interventions - of which Luminopia is the first listed.
NCT06524882 names 20 study sites across 7 states, led by California, Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT06524882 about?
NCT06524882 is a clinical study titled "Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age". Participants eligible for the study will be randomly allocated (1:1:1) to receive either Luminopia dichoptic treatment while wearing optical correction if needed, Vivid Vision dichoptic treatment while wearing optical correction if needed, or continued optical correction alone if needed, with clinic...
What is the current status of trial NCT06524882?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 252 participants. The study started on 2024-10-22. Estimated completion is 2027-11-01.
What conditions does trial NCT06524882 study?
This clinical trial studies the following conditions: Amblyopia.
What interventions are being tested in trial NCT06524882?
The interventions under investigation include: Luminopia (DEVICE), Vivid Vision (DEVICE), Optical Correction (DEVICE).
Who is sponsoring clinical trial NCT06524882?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06524882 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amblyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06524882's enrollment target sits among peer trials
252 5th of 24 higher than 20 of 24 other Amblyopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amblyopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
RECRUITING · Phase 3
-
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
RECRUITING · Phase 3
-
Amblyopia (Lazy Eye) Treatment Study
COMPLETED · Phase 3
-
Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children
COMPLETED · Phase 3
-
Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old
COMPLETED · Phase 3
-
Trial Comparing Part-time Versus Full-time Patching for Severe Amblyopia
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- NCT05384158 · 252 participants · NA
Valuation in Depressed Mood, Anhedonia, and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI